Louis Edward Tamayo, Chief Financial Officer at Lexeo Therapeutics, sold LXEO on Jul 1, 2026
Data as of Oct 27
▼ SELL$20.8K4,641 shares at $4.49Louis Edward Tamayo Chief Financial OfficerLXEO Lexeo Therapeutics, Inc.
- Traded
- Jul 1, 2026
- Disclosed
- Jul 1, 2026
- Filed
- The same day
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
LXEO since disclosure
−35.5%
after the sale
Similar stocks (XLV) since disclosure
+12.3%
XLV — its sector index fund
Change in closing price from Jul 1, 2026 (the first trading day on or after disclosure) to Oct 27, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.